MARKET

CRIS

CRIS

Curis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.00
+0.31
+3.20%
Opening 13:24 02/24 EST
OPEN
9.85
PREV CLOSE
9.69
HIGH
10.16
LOW
9.63
VOLUME
433.95K
TURNOVER
--
52 WEEK HIGH
13.44
52 WEEK LOW
0.6200
MARKET CAP
823.05M
P/E (TTM)
-12.1907
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Steven Cohen Dives Into Chimerix
GuruFocus News · 3h ago
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Analysis, Size, Share, Trends and Forecast 2020-2027
pune, India, Mon, 22 Feb 2021 04:53:41 / Comserve Inc. / -- Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform market is segmented...
Comserve · 2d ago
Global Histone Deacetylase 1 Market Analysis, Growth, Size, Share, Trends, Forecast, Supply Demand and Sales to 2027
Feb 22, 2021 (The Expresswire) -- Global “Histone Deacetylase 1 Market” forecast 2027; research report analyzed the existing state of the market by...
The Express Wire · 2d ago
Global Histone Deacetylase 2 Market 2021 Manufacturers, Suppliers and Export Research Report and Forecast to 2027
Feb 22, 2021 (The Expresswire) -- Global “Histone Deacetylase 2 Market” forecast 2027; research report analyzed the existing state of the market by...
The Express Wire · 2d ago
Histone Deacetylase 1 Market Application, Product Segment, Analysis and Forecast 2020-2027 Report By Ameco Research
pune, India, Mon, 22 Feb 2021 02:49:26 / Comserve Inc. / -- Histone Deacetylase 1 market is segmented by Type, and by Application. Players, stakeholders, and...
Comserve · 2d ago
Histone Deacetylase 2 Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2020-2027 By Ameco Research
Comserve · 2d ago
Histone Deacetylase 6 Market Segmented Application and Geography Trends, Growth and Forecasts to 2020 - 2027 By Ameco Research
pune, India, Mon, 22 Feb 2021 00:38:01 / Comserve Inc. / -- Histone Deacetylase 6 market is segmented by Type, and by Application. Players, stakeholders, and...
Comserve · 2d ago
Curis to Present at SVB Leerink 10th Annual Global Healthcare Conference
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present a company overview at th...
PR Newswire · 5d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CRIS. Analyze the recent business situations of Curis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CRIS stock price target is 15.75 with a high estimate of 18.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 123
Institutional Holdings: 67.32M
% Owned: 81.79%
Shares Outstanding: 82.31M
TypeInstitutionsShares
Increased
27
7.77M
New
58
39.50M
Decreased
13
4.38M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.30%
Pharmaceuticals & Medical Research
+1.31%
Key Executives
Chairman/Independent Director
Martyn Greenacre
President/Chief Executive Officer/Director
James Dentzer
Chief Financial Officer
William Steinkrauss
Other
Robert Martell
Independent Director
Kenneth Kaitin
Independent Director
Lori Kunkel
Independent Director
Marc Rubin
  • Dividends
  • Splits
  • Insider Activity
No Data
About CRIS
Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.

Webull offers kinds of Curis, Inc. stock information, including NASDAQ:CRIS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRIS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRIS stock methods without spending real money on the virtual paper trading platform.